Honghui Capital Jiang Yanye: "Full Cycle + Whole Industry", Medical Fund Play Is Also Changing.

Since January of this year, Kanglong has been listed in the Hong Kong stock exchange, and the pharmaceutical industry has been listed on the Hong Kong stock exchange. In addition, Sheng Xiang biology, Kai Yin technology, Kam Mei diagnostics and kin tech are listed in the various stages of listing and listing.

Under the background of the slowing down of the global IPO rhythm, the Hongkong capital investment project has broken through in various capital markets.

"Everyone's enthusiasm for investing in health is still high, and I believe this is an industry that is worth investing in the next few years." Referring to PE/VC's attention to the health field, Jiang Yanye, Honghui capital partners, said.

Honghui capital Jiang Yanye. Data map

During the new crown outbreak in 2020, MINDRAY, dive, united vision, and San Xiang were also the medical corps behind the fire god mountain and Raytheon hill. These enterprises also have a common identity - Honghui capital health industry ecology member enterprises.

The value orientation of Honghui capital was "an open platform for healthy entrepreneurs and entrepreneurs." On the one hand, this is a lot of investment veterans as a new fund team's entrepreneurship, on the other hand, they have closer cooperation with the invested enterprises and entrepreneurs, hoping to jointly build an investment platform for such industries.

Six years later, the core framework of the foregoing vision has basically taken shape. Hong Hui's management scale has increased from more than ten billion yuan at the beginning of its establishment to more than 10 billion yuan nowadays. Deep tillage and healthy early investment also continue to increase the subsequent financing of quality projects.

From the perspective of health industry ecological construction, Honghui has invested in more than 60 companies, corresponding to professional circles in various fields, including medical enterprise founders, pharmaceutical factory entrepreneurs and chain hospital managers.

The positioning of the healthy global professional fund requires Honghui capital to do more research on the industry before its investment and value-added services after its investment.

Jiang Yanye introduced Honghui capital to cover various sectors of the medical industry through in-depth industry research. The strategy has been investing in innovative biotechnology, medical innovation derivative track and health service subdivision.

In April this year, Zentalis, an anticancer drug research and development company, was listed on NASDAQ. Honghui capital is the B round leader of Zentalis, and has been involved in several rounds of financing.

In addition to the innovative pharmaceutical research and development enterprises including Zentalis, Honghui capital has invested in CRO enterprises such as pharmaceutical products, Kanglong and so on, as well as health services companies such as Marco dentistry, universal healthcare and Beaba.

"We have been discussing the definition of investment stage and focus on the industry. We must make certain configuration in every subdivision industry and establish a better framework for risk and return balance. " Jiang Yanye said that the amount of a single investment should be kept within a certain range, and it is also for better and more focused consideration of the post investment service for the invested enterprises.